**S. Table 3.** Meta-analysis of proportion of COVID-19 positive patients receiving KRT for AKI management across different studies.

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Event/Sample size** | **Proportion (%) (95% CI)** | **Random Weight (%)** |
| Chan, L et al., 2020 | 280/1406 | 19.92% (17.86% - 22.1%) | 28.49 |
| Muner, M et al., 2020 | 89/161 | 55.28% (47.25% - 63.11%) | 27.87 |
| Pei, G et al., 2020 | 6/35 | 17.14% (6.56% - 33.65%) | 25.64 |
| Wu, H et al., 2020 | 5/6 | 83.33% (35.88 to 99.5) | 18.00 |
| Total (random effects) | 380/1,608 | 39.04% (16.38% - 64.57%) | 100 |